Table 3.

Relationship between each of the biomarkers (C1M, C5M, C6M and VICM) and 2-year mSASSS change (unadjusted and adjusted models)

	C1M	C5M	C6M	VICM
	β (95% CI)	β (95% CI)	β (95% CI)	β (95% CI)
Unadjusted	0.01 (0.00 to 0.03)	−0.00 (-0.12 to 0.11)	−0.00 (-0.03 to 0.02)	−0.00 (-0.03 to 0.02)
Adjusted for age, gender and symptom duration	0.02 (-0.00 to 0.04)	−0.02 (-0.15 to 0.10)	−0.00 (-0.03 to 0.03)	−0.00 (-0.03 to 0.03)
Adjusted for age, gender, symptom duration and baseline mSASSS	0.02 (-0.00 to 0.03)	−0.01 (-0.14 to 0.11)	−0.00 (-0.03 to 0.03)	0.00 (-0.03 to 0.03)
Adjusted for age, gender, symptom duration, mSASSS and CRP	0.00 (-0.03 to 0.03)	−0.00 (-0.12 to 0.12)	−0.01 (-0.04 to 0.02)	−0.03 (-0.06 to 0.00)
Adjusted for age, gender, symptom duration, mSASSS and ASDAS	0.02 (-0.01 to 0.04)	−0.01 (-0.14 to 0.11)	−0.00 (-0.03 to 0.02)	−0.00 (-0.03 to 0.03)

ASDAS, Ankylosing Spondylitis Disease Activity Index; C1M, C5M and C6M, MMP-mediated degradation of type I, V and VI collagen; respectively; CRP, C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine; MMP, matrix metalloproteinase; VICM, citrullinated and MMP-degraded vimentin.